{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,6,3]],"date-time":"2025-06-03T16:46:49Z","timestamp":1748969209312,"version":"3.37.3"},"reference-count":20,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,12,21]],"date-time":"2024-12-21T00:00:00Z","timestamp":1734739200000},"content-version":"am","delay-in-days":264,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100000026","name":"National Institute on Drug Abuse","doi-asserted-by":"publisher","award":["R01DA046527","P30DA040500","1T32DA041898-01A1"],"award-info":[{"award-number":["R01DA046527","P30DA040500","1T32DA041898-01A1"]}],"id":[{"id":"10.13039\/100000026","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["jsatjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Substance Use and Addiction Treatment"],"published-print":{"date-parts":[[2024,4]]},"DOI":"10.1016\/j.josat.2023.209281","type":"journal-article","created":{"date-parts":[[2023,12,19]],"date-time":"2023-12-19T00:28:42Z","timestamp":1702945722000},"page":"209281","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Out-of-pocket spending and health care utilization associated with initiation of different medications for opioid use disorder: Findings from a national commercially insured cohort"],"prefix":"10.1016","volume":"159","author":[{"given":"Nicole C.","family":"McCann","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marc R.","family":"LaRochelle","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jake R.","family":"Morgan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.josat.2023.209281_bb0005","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1093\/cid\/ciaa062","article-title":"Outcomes associated with medications for opioid use disorder among persons hospitalized for infective endocarditis","volume":"72","author":"Barocas","year":"2021","journal-title":"Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America"},{"issue":"3","key":"10.1016\/j.josat.2023.209281_bb0010","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1111\/ajad.12711","article-title":"Antagonists in the medical management of opioid use disorders: Historical and existing treatment strategies","volume":"27","author":"Bisaga","year":"2018","journal-title":"The American Journal on Addictions"},{"issue":"10182","key":"10.1016\/j.josat.2023.209281_bb0015","doi-asserted-by":"crossref","first-page":"1760","DOI":"10.1016\/S0140-6736(18)33078-2","article-title":"Management of opioid use disorder in the USA: Present status and future directions","volume":"393","author":"Blanco","year":"2019","journal-title":"Lancet (London, England)"},{"issue":"May","key":"10.1016\/j.josat.2023.209281_bb0020","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/j.drugalcdep.2014.02.701","article-title":"Factors predicting development of opioid use disorders among individuals who receive an initial opioid prescription: Mathematical modeling using a database of commercially-insured individuals","volume":"138","author":"Cochran","year":"2014","journal-title":"Drug and Alcohol Dependence"},{"issue":"August","key":"10.1016\/j.josat.2023.209281_bb0025","article-title":"Do out-of-pocket costs influence retention and adherence to medications for opioid use disorder?","volume":"225","author":"Dunphy","year":"2021","journal-title":"Drug and Alcohol Dependence"},{"issue":"10118","key":"10.1016\/j.josat.2023.209281_bb0030","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/S0140-6736(17)32812-X","article-title":"Comparative effectiveness of extended-release naltrexone versus buprenorphine-naloxone for opioid relapse prevention (X:BOT): A multicentre, open-label, randomised controlled trial","volume":"391","author":"Lee","year":"2018","journal-title":"Lancet (London, England)"},{"key":"10.1016\/j.josat.2023.209281_bb0035","series-title":"Merative MarketScan Research Databases","volume":"2022","author":"Merative","year":"2022"},{"issue":"3","key":"10.1016\/j.josat.2023.209281_bb0040","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1097\/MLR.0000000000001689","article-title":"Variation in initiation, engagement, and retention on medications for opioid use disorder based on health insurance plan design","volume":"60","author":"Morgan","year":"2022","journal-title":"Medical Care"},{"issue":"February","key":"10.1016\/j.josat.2023.209281_bb0045","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.jsat.2017.07.001","article-title":"Injectable naltrexone, oral naltrexone, and buprenorphine utilization and discontinuation among individuals treated for opioid use disorder in a United States commercially insured population","volume":"85","author":"Morgan","year":"2018","journal-title":"Journal of Substance Abuse Treatment"},{"issue":"July","key":"10.1016\/j.josat.2023.209281_bb0050","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.drugalcdep.2019.02.031","article-title":"Overdose following initiation of naltrexone and buprenorphine medication treatment for opioid use disorder in a United States commercially insured cohort","volume":"200","author":"Morgan","year":"2019","journal-title":"Drug and Alcohol Dependence"},{"issue":"2","key":"10.1016\/j.josat.2023.209281_bb0055","doi-asserted-by":"crossref","first-page":"90","DOI":"10.7326\/M18-0227","article-title":"Cost-effectiveness of buprenorphine-naloxone versus extended-release naltrexone to prevent opioid relapse","volume":"170","author":"Murphy","year":"2019","journal-title":"Annals of Internal Medicine"},{"author":"National Institute on Drug Abuse","key":"10.1016\/j.josat.2023.209281_bb0060"},{"year":"2023","series-title":"\"Drug Overdose Death Rates.\"","author":"National Institute on Drug Abuse","key":"10.1016\/j.josat.2023.209281_bb5000"},{"issue":"10","key":"10.1016\/j.josat.2023.209281_bb0065","doi-asserted-by":"crossref","first-page":"2072","DOI":"10.1016\/j.mayocp.2019.03.029","article-title":"Medication-assisted treatment for opioid-use disorder","volume":"94","author":"Oesterle","year":"2019","journal-title":"Mayo Clinic Proceedings"},{"author":"Patient-Centered Outcomes Research Institute","key":"10.1016\/j.josat.2023.209281_bb0070"},{"issue":"2","key":"10.1016\/j.josat.2023.209281_bb0075","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1038\/s41433-021-01863-w","article-title":"The clinician\u2019s guide to p values, confidence intervals, and magnitude of effects","volume":"36","author":"Phillips","year":"2022","journal-title":"Eye (London, England)"},{"issue":"19","key":"10.1016\/j.josat.2023.209281_bb0080","first-page":"335","article-title":"Confidence interval or P-value?: Part 4 of a series on evaluation of scientific publications","volume":"106","author":"Prel","year":"2009","journal-title":"Deutsches Arzteblatt International"},{"issue":"4","key":"10.1016\/j.josat.2023.209281_bb0085","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1080\/13696998.2018.1427101","article-title":"Healthcare utilization and costs associated with treatment for opioid dependence","volume":"21","author":"Shah","year":"2018","journal-title":"Journal of Medical Economics"},{"issue":"2","key":"10.1016\/j.josat.2023.209281_bb0090","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2022.54590","article-title":"Trends in out-of-pocket costs for and characteristics of pharmacy-dispensed buprenorphine medications for opioid use disorder treatment by type of payer, 2015 to 2020","volume":"6","author":"Strahan","year":"2023","journal-title":"JAMA Network Open"},{"author":"U.S. Department of Health & Human Services","key":"10.1016\/j.josat.2023.209281_bb0095"}],"container-title":["Journal of Substance Use and Addiction Treatment"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2949875923003338?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2949875923003338?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,10,10]],"date-time":"2024-10-10T16:46:49Z","timestamp":1728578809000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2949875923003338"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4]]},"references-count":20,"alternative-id":["S2949875923003338"],"URL":"https:\/\/doi.org\/10.1016\/j.josat.2023.209281","relation":{},"ISSN":["2949-8759"],"issn-type":[{"type":"print","value":"2949-8759"}],"subject":[],"published":{"date-parts":[[2024,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Out-of-pocket spending and health care utilization associated with initiation of different medications for opioid use disorder: Findings from a national commercially insured cohort","name":"articletitle","label":"Article Title"},{"value":"Journal of Substance Use and Addiction Treatment","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.josat.2023.209281","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"209281"}}